Be the first person to write a business review for Adherex Technologies Inc.

Adnexus Therapeutics, Inc. engages in the discovery, development, and commercialization of Adnectins biologics/medicines in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Co.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.

Advanced Life Sciences Holdings, Inc. company was founded in 1999 and is headquartered in Woodridge, Illinois. Advanced Life Sciences Holdings, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and respiratory disease. The Company has assembled a pipeline of clinical and preclinical product candidates. In September 2008, the Company entered into a development and commercialization agreement with Wyeth for cethromycin in the Asia Pacific region excluding Japan. Advanced Life Sciences Holdings, Inc. has a worldwide license (excluding Japan) from Abbott Laboratories (Abbott) to develop and commercialize cethromycin, once-a-day antibiotic for the treatment of respiratory tract infections. On September 30, 2008, the Company submitted a new drug application for the use of cethromycin in community acquired pneumonia.

The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates. Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs. Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies to commercially viable proteins. The technology is applicable to the generation of a variety of protein products including protein therapeutics, protein diagnostics and high value reagents for research.

ADVENTRX Pharmaceuticals, Inc. company was founded in 1995 is based in San Diego, California. ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.